Rapid diagnosis of SARS-CoV-2 using potential point-of-care electrochemical immunosensor: Toward the future prospects

Ranjan, Pushpesh; Singhal, Ayushi; Yadav, Shalu; Kumar, Neeraj; Murali, Sharan; Sanghi, Sunil Kumar; Khan, Raju

doi:10.1080/08830185.2021.1872566

Cited by 61 publications

(45 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Brazil, specifically, the development of these devices based on the national sample of patients appears as an essential and necessary opportunity for the development of national technology with low cost and accessibility, in order to minimize the bringing down effect on the health system. Hence, developing novel electrochemical biosensors based on the detection of antigen-antibody interactions or membrane proteins of SARS-CoV-2 appears as an adequate and accessible alternative of test devices to those based on reverse transcription-polymerase chain reaction (RT-PCR) to supply the world’s current demand [ 3 , 4 , 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

A Novel Method for the Detection of SARS-CoV-2 Based on Graphene-Impedimetric Immunosensor

et al. 2021

View full text Add to dashboard Cite

Due to the SARS-CoV-2 pandemic, there has been an increase in the search for affordable healthcare devices for mass testing and rapid diagnosis. In this context, this work described a new methodology for SARS-CoV-2 detection based on an impedimetric immunosensor developed using the advantageous immobilization of antibodies in the reduced graphene oxide (rGO). The rGO was obtained by chemical synthesis from the commercial graphene oxide (GO), and the materials were morphologically, electrochemically and visually characterized. The cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) techniques were used to evaluate the fabrication steps of the immunosensor. The electrochemical immunoassay was considered for SARS-CoV-2 spike protein RBD detection using a impedimetric immunosensor and redox couple ([(Fe(CN)6)]3−/4−) as a probe. The immunosensor was effectively developed and applied in the detection of SARS-CoV-2 spike protein RBD in saliva samples.

show abstract

Section: Introductionmentioning

confidence: 99%

A Novel Method for the Detection of SARS-CoV-2 Based on Graphene-Impedimetric Immunosensor

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Electrochemical immunosensor (EC) can be used for viral analysis [229]. An electrochemical immunosensor based on an array of carbon electrodes (DEP)/Au NPs was reported to detect the recombinant on the surface of microfluidic channels [230].…”

Section: Antigen-bases Methodsmentioning

confidence: 99%

Nanobiotechnology as a platform for the diagnosis of COVID-19: a review

Abdelhamid

Badr

2021

Nanotechnol. Environ. Eng.

View full text Add to dashboard Cite

A sensitive method for diagnosing coronavirus disease 2019 (COVID-19) is highly required to fight the current and future global health threats due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2). However, most of the current methods exhibited high false-negative rates, resulting in patient misdiagnosis and impeding early treatment. Nanoparticles show promising performance and great potential to serve as a platform for diagnosing viral infection in a short time and with high sensitivity. This review highlighted the potential of nanoparticles as platforms for the diagnosis of COVID-19. Nanoparticles such as gold nanoparticles, magnetic nanoparticles, and graphene (G) were applied to detect SARS-CoV 2. They have been used for molecular-based diagnosis methods and serological methods. Nanoparticles improved specificity and shorten the time required for the diagnosis. They may be implemented into small devices that facilitate the self-diagnosis at home or in places such as airports and shops. Nanoparticles-based methods can be used for the analysis of virus-contaminated samples from a patient, surface, and air. The advantages and challenges were discussed to introduce useful information for designing a sensitive, fast, and low-cost diagnostic method. This review aims to present a helpful survey for the lesson learned from handling this outbreak to prepare ourself for future pandemic.

show abstract

“…Several of these devices were shown to provide accurate results in as little as 10 min, though they can average around 30 min. The improvement in rapid testing, sensitivity and selectivity gained from microfluidic integration is something that these devices can take advantage of in the clinical translation of these diagnostic tools from general pathogens to on-site SARS-CoV-2 testing [ 95 , 96 ].…”

Section: Using Imps In the On-site Detection Of Infectious Pathogensmentioning

confidence: 99%

Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms

Escobar

Chiu

et al. 2021

Micromachines

View full text Add to dashboard Cite

The rapid detection and quantification of infectious pathogens is an essential component to the control of potentially lethal outbreaks among human populations worldwide. Several of these highly infectious pathogens, such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been cemented in human history as causing epidemics or pandemics due to their lethality and contagiousness. SARS-CoV-2 is an example of these highly infectious pathogens that have recently become one of the leading causes of globally reported deaths, creating one of the worst economic downturns and health crises in the last century. As a result, the necessity for highly accurate and increasingly rapid on-site diagnostic platforms for highly infectious pathogens, such as SARS-CoV-2, has grown dramatically over the last two years. Current conventional non-microfluidic diagnostic techniques have limitations in their effectiveness as on-site devices due to their large turnaround times, operational costs and the need for laboratory equipment. In this review, we first present criteria, both novel and previously determined, as a foundation for the development of effective and viable on-site microfluidic diagnostic platforms for several notable pathogens, including SARS-CoV-2. This list of criteria includes standards that were set out by the WHO, as well as our own “seven pillars” for effective microfluidic integration. We then evaluate the use of microfluidic integration to improve upon currently, and previously, existing platforms for the detection of infectious pathogens. Finally, we discuss a stage-wise means to translate our findings into a fundamental framework towards the development of more effective on-site SARS-CoV-2 microfluidic-integrated platforms that may facilitate future pandemic diagnostic and research endeavors. Through microfluidic integration, many limitations in currently existing infectious pathogen diagnostic platforms can be eliminated or improved upon.

show abstract

Rapid diagnosis of SARS-CoV-2 using potential point-of-care electrochemical immunosensor: Toward the future prospects

Cited by 61 publications

References 102 publications

A Novel Method for the Detection of SARS-CoV-2 Based on Graphene-Impedimetric Immunosensor

A Novel Method for the Detection of SARS-CoV-2 Based on Graphene-Impedimetric Immunosensor

Nanobiotechnology as a platform for the diagnosis of COVID-19: a review

Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms

Contact Info

Product

Resources

About